Tuberculosis and Respiratory Diseases

  • 제67권2호
  • /
  • Pages.95-104
  • /
  • 2009
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

리포다당질로 인한 직접성 급성폐손상에서 Nuclear Factor-κB Decoy Oligodeoxynucleotide의 효과

The Effects of Nuclear Factor-κB Decoy Oligodeoxynucleotide on Lipopolysaccharide-Induced Direct Acute Lung Injury

  • 김제형 (고려대학교 의과대학 안산병원 호흡기내과) ;
  • 윤대위 (고려대학교 의과대학 안산병원 호흡기내과) ;
  • 정기환 (고려대학교 의과대학 안산병원 호흡기내과) ;
  • 김혜옥 (고려대학교 의과대학 구로병원 호흡기내과) ;
  • 하은실 (고려대학교 의과대학 안암병원 호흡기내과) ;
  • 이경주 (고려대학교 의과대학 구로병원 호흡기내과) ;
  • 허규영 (고려대학교 의과대학 구로병원 호흡기내과) ;
  • 이승룡 (고려대학교 의과대학 구로병원 호흡기내과) ;
  • 이상엽 (고려대학교 의과대학 안암병원 호흡기내과) ;
  • 신철 (고려대학교 의과대학 안산병원 호흡기내과) ;
  • 심재정 (고려대학교 의과대학 구로병원 호흡기내과) ;
  • 인광호 (고려대학교 의과대학 안암병원 호흡기내과) ;
  • 유세화 (고려대학교 의과대학 안암병원 호흡기내과) ;
  • 강경호 (고려대학교 의과대학 구로병원 호흡기내과)
  • Kim, Je Hyeong (Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Yoon, Dae Wui (Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Jung, Ki Hwan (Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Kim, Hye Ok (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Ha, Eun Sil (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital) ;
  • Lee, Kyoung Ju (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Hur, Gyu Young (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Lee, Sung Yong (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Lee, Sang Yeub (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital) ;
  • Shin, Chol (Division of Pulmonary, Sleep and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Shim, Jae Jeong (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital) ;
  • In, Kwang Ho (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital) ;
  • Yoo, Se Hwa (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital) ;
  • Kang, Kyung Ho (Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital)
  • 투고 : 2009.05.20
  • 심사 : 2009.07.02
  • 발행 : 2009.08.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The pathophysiologic mechanisms of early acute lung injury (ALI) differ according to the type of primary insult. It is important to differentiate between direct and indirect pathophysiologic pathways, and this may influence the approach to treatment strategies. NF-$\kappa$B decoy oligodeoxynucleotide (ODN) is a useful tool for the blockade of the expression of NF-$\kappa$B-dependent proinflammatory mediators and has been reported to be effective in indirect ALI. The purpose of this study was to investigate the effect of NF-$\kappa$B decoy ODN in the lipopolysaccharide (LPS)-induced direct ALI model. Methods: Five-week-old specific pathogen-free male BALB/c mice were used for the experiment. In the preliminary studies, tumor necrosis factor (TNF)-$\alpha$, interleukine (IL)-6 and NF-$\kappa$B activity peaked at 6 hours after LPS administration. Myeloperoxidase (MPO) activity and ALI score were highest at 36 and 48 hours, respectively. Therefore, it was decided to measure each parameter at the time of its highest level. The study mice were randomly divided into three experimental groups: (1) control group which was administered 50 ${\mu}L$ of saline and treated with intratracheal administration of 200 ${\mu}L$ DW containing only hemagglutinating virus of Japan (HVJ) vector (n=24); (2) LPS group in which LPS-induced ALI mice were treated with intratracheal administration of 200 ${\mu}L$ DW containing only HVJ vector (n=24); (3) LPS+ODN group in which LPS-induced ALI mice were treated with intratracheal administration of 200 ${\mu}L$ DW containing 160 ${\mu}g$ of NF-$\kappa$B decoy ODN and HVJ vector (n=24). Each group was subdivided into four experimental subgroups: (1) tissue subgroup for histopathological examination for ALI at 48 hours (n=6); (2) 6-hour bronchoalveolar lavage (BAL) subgroup for measurement of TNF-$\alpha$ and IL-6 in BAL fluid (BALF) (n=6); (3) 36-hour BAL subgroup for MPO activity assays in BALF (n=6); and (4) tissue homogenate subgroup for measurement of NF-$\kappa$B activity in lung tissue homogenates at 6 hours (n=6). Results: NF-$\kappa$B decoy ODN treatment significantly decreased NF-$\kappa$B activity in lung tissues. However, it failed to improve the parameters of LPS-induced direct ALI, including the concentrations of tumor necrosis factor-$\alpha$ and interleukin-6 in BALF, myeloperoxidase activity in BALF and histopathologic changes measured by the ALI score. Conclusion: NF-$\kappa$B decoy ODN, which has been proven to be effective in indirect models, had no effect in the direct ALI model.

키워드

참고문헌

  1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24 https://doi.org/10.1164/ajrccm.149.3.7509706
  2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-93 https://doi.org/10.1056/NEJMoa050333
  3. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8 https://doi.org/10.1056/NEJM200005043421801
  4. Gattinoni L, Caironi P, Pelosi P, Goodman LR. What has computed tomography taught us about the acute respiratory distress syndrome? Am J Respir Crit Care Med 2001;164:1701-11 https://doi.org/10.1164/ajrccm.164.9.2103121
  5. Leeper-Woodford SK, Detmer K. Acute hypoxia increases alveolar macrophage tumor necrosis factor activity and alters NF-kappaB expression. Am J Physiol 1999;276:L909-16
  6. Moine P, McIntyre R, Schwartz MD, Kaneko D, Shenkar R, Le Tulzo Y, et al. NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock 2000;13:85-91
  7. Pepperl S, Dorger M, Ringel F, Kupatt C, Krombach F. Hyperoxia upregulates the NO pathway in alveolar macrophages in vitro: role of AP-1 and NF-kappaB. Am J Physiol Lung Cell Mol Physiol 2001;280:L905-13 https://doi.org/10.1152/ajplung.2001.280.5.L905
  8. Pugin J, Dunn I, Jolliet P, Tassaux D, Magnenat JL, Nicod LP, et al. Activation of human macrophages by mechanical ventilation in vitro. Am J Physiol 1998;275:L1040-50 https://doi.org/10.1152/ajpcell.1998.275.4.C1040
  9. Shenkar R, Yum HK, Arcaroli J, Kupfner J, Abraham E. Interactions between CBP, NF-kappaB, and CREB in the lungs after hemorrhage and endotoxemia. Am J Physiol Lung Cell Mol Physiol 2001;281:L418-26 https://doi.org/10.1152/ajplung.2001.281.2.L418
  10. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 1999;274:27339-42 https://doi.org/10.1074/jbc.274.39.27339
  11. Nathens AB, Bitar R, Davreux C, Bujard M, Marshall JC, Dackiw AP, et al. Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol 1997;17:608-16 https://doi.org/10.1165/ajrcmb.17.5.2661
  12. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-103 https://doi.org/10.1074/jbc.272.34.21096
  13. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, Zingarelli B. Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 2002;61:953-63 https://doi.org/10.1124/mol.61.5.953
  14. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990;250:997-1000 https://doi.org/10.1126/science.2237444
  15. Matsuda N, Hattori Y, Jesmin S, Gando S. Nuclear factor-kappaB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 2005;67:1018-25 https://doi.org/10.1124/mol.104.005926
  16. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998;82:1023-8 https://doi.org/10.1161/01.RES.82.10.1023
  17. Igwe OJ. Modulation of peripheral inflammation in sensory ganglia by nuclear factor (kappa)B decoy oligodeoxynucleotide: involvement of SRC kinase pathway. Neurosci Lett 2005;381:114-9 https://doi.org/10.1016/j.neulet.2005.02.020
  18. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Jo N, et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004;109:132-8 https://doi.org/10.1161/01.CIR.0000105725.61763.A2
  19. Ogushi I, Iimuro Y, Seki E, Son G, Hirano T, Hada T, et al. Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model. Hepatology 2003;38:335-44
  20. Xu MQ, Shuai XR, Yan ML, Zhang MM, Yan LN. Nuclear factor-kappaB decoy oligodeoxynucleotides attenuates ischemia/reperfusion injury in rat liver graft. World J Gastroenterol 2005;11:6960-7 https://doi.org/10.3748/wjg.v11.i44.6960
  21. Yokoseki O, Suzuki J, Kitabayashi H, Watanabe N, Wada Y, Aoki M, et al. cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001;89:899-906 https://doi.org/10.1161/hh2201.099373
  22. Matsuda N, Hattori Y, Takahashi Y, Nishihira J, Jesmin S, Kobayashi M, et al. Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol 2004;287:L1248-55 https://doi.org/10.1152/ajplung.00164.2004
  23. Pelosi P, D'Onofrio D, Chiumello D, Paolo S, Chiara G, Capelozzi VL, et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J Suppl 2003;42:48s-56s
  24. Bachofen M, Weibel ER. Alterations of the gas exchange apparatus in adult respiratory insufficiency as-sociated with septicemia. Am Rev Respir Dis 1977;116:589-615 https://doi.org/10.1164/arrd.1977.116.4.589
  25. Blaisdell FW. Pathophysiology of the respiratory distress syndrome. Arch Surg 1974;108:44-9 https://doi.org/10.1001/archsurg.1974.01350250036009
  26. Lamy ML, Fallat RJ, Koeniger EL, Dietrich HP, Kamm B, Hill JD. Pathophysiology of adult respiratory distress syndrome. Acta Anaesthesiol Belg 1975;23 Suppl:64-77
  27. Nash G, Foley FD, Langlinais PC. Pulmonary interstitial edema and hyaline membranes in adult burn patients. Electron microscopic observations. Hum Pathol 1974;5:149-60 https://doi.org/10.1016/S0046-8177(74)80062-6
  28. Callister ME, Evans TW. Pulmonary versus extrapulmonary acute respiratory distress syndrome: different diseases or just a useful concept? Curr Opin Crit Care 2002;8:21-5 https://doi.org/10.1097/00075198-200202000-00004
  29. Rocco PR, Zin WA. Pulmonary and extrapulmonary acute respiratory distress syndrome: are they different? Curr Opin Crit Care 2005;11:10-7 https://doi.org/10.1097/00075198-200502000-00003
  30. Kim JH, Suk MH, Yoon DW, Lee SH, Hur GY, Jung KH, et al. Inhibition of matrix metalloproteinase-9 prevents neutrophilic inflammation in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2006;291:L580-7 https://doi.org/10.1152/ajplung.00270.2005
  31. Hirano S. Migratory responses of PMN after intraperitoneal and intratracheal administration of lipopolysaccharide. Am J Physiol 1996;270:L836-45
  32. Harada K, Ohira S, Isse K, Ozaki S, Zen Y, Sato Y, et al. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest 2003;83:1657-67 https://doi.org/10.1097/01.LAB.0000097190.56734.FE
  33. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, et al. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 2001;29:E21 https://doi.org/10.1093/nar/29.4.e21
  34. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, et al. In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-9 https://doi.org/10.1038/nm0897-894
  35. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002;6:219-26 https://doi.org/10.1006/mthe.2002.0647
  36. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49 https://doi.org/10.1056/NEJM200005043421806
  37. Menezes SL, Bozza PT, Neto HC, Laranjeira AP, Negri EM, Capelozzi VL, et al. Pulmonary and extrapulmonary acute lung injury: inflammatory and ultrastructural analyses. J Appl Physiol 2005;98:1777-83 https://doi.org/10.1152/japplphysiol.01182.2004
  38. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 2001;8:1635-42 https://doi.org/10.1038/sj.gt.3301566
  39. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 2006;12:151-70 https://doi.org/10.1179/096805106X102246
  40. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, et al. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2003;167:1027-35 https://doi.org/10.1164/rccm.200208-966WS